STRS Ohio’s Viridian Therapeutics VRDN Stock Holding History

STRS Ohio’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82.7K	Sell	4,500 -16,800	-79%	-$271K	﹤0.01%	1914
2026 Q1	$417K	Buy	+21,300	New	+$633K	﹤0.01%	1180
2023 Q2	–	Sell	-800	Closed	-$20K	–	2112
2023 Q1	$20K	Buy	+800	New	+$25.7K	﹤0.01%	1867
2018 Q2	–	Sell	-247	Closed	-$25K	–	2184
2018 Q1	$25K	Hold	247	–	–	﹤0.01%	1806
2017 Q4	$38K	Hold	247	–	–	﹤0.01%	1780
2017 Q3	$33K	Hold	247	–	–	﹤0.01%	1838
2017 Q2	$47K	Buy	+247	New	+$41.7K	﹤0.01%	1802

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

STRS Ohio's VRDN Position: Q2 2026 in Review

STRS Ohio reduced its Viridian Therapeutics (VRDN) stake by 79% in Q2 2026, selling an estimated $271K and leaving 4,500 shares worth $82.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

STRS Ohio first reported a position in VRDN in Q2 2017 and has held it in 7 quarters since. The position peaked at $417K in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

STRS Ohio held 4,500 shares of Viridian Therapeutics worth $82.7K as of Q2 2026.
STRS Ohio sold 16,800 Viridian Therapeutics shares in Q2 2026, an estimated $271K.
Viridian Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1914 holding.
STRS Ohio first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 7 quarters since.
STRS Ohio's Viridian Therapeutics position peaked at $417K in Q1 2026.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.